Laura J Martins

Dr. Laura J Martins

University of Utah School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Cell Cycle
Verified
Journal Article
Closed access
DBDaniela Boehm
Daniela Boehm
VCVincenzo Calvanese
Vincenzo Calvanese
RDRoy D. Dar
Roy D. Dar
SXSifei Xing
Sifei Xing
SSSebastian Schroeder
Sebastian Schroeder
MOMelanie Ott
Melanie Ott
The therapeutic potential of pharmacologic inhibition of bromodomain and extraterminal (BET) proteins has recently emerged in hematological malignancies and chronic inflammation. We find that BET i...

1 September 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Laura J MartinsLaura J Martins
Laura J Martins
LJLaran Jensen
Laran Jensen
JSJohn R. Simon
John R. Simon
GKGreg L. Keller
Greg L. Keller
DWDennis R. Winge
Dennis R. Winge
The high affinity uptake systems for iron and copper ions in Saccharomyces cerevisiae involve metal-specific permeases and two known cell surface Cu(II) and Fe(III) metalloreductases, Fre1 and Fre2. Five novel genes found in theS. cerevisiae genome exhibit marked sequence similarity to Fre1 and Fre2, suggesting that the homologs are part of a family of proteins related to Fre1 and Fre2. The homologs are expressed genes inS. cerevisiae, and their expression is metalloregulated as is true with FRE1 and FRE2. Four of the homologs (FRE3-FRE6) are specifically iron-regulated through the Aft1 transcription factor. These genes are expressed either in cells limited for iron ion uptake by treatment with a chelator or in cells lacking the high affinity iron uptake system. Expression of FRE3-FRE6 is elevated inAFT1–1 cells and attenuated in aft1null cells, showing that iron modulation occurs through the Aft1 transcriptional activator. The fifth homolog FRE7 is specifically copper-metalloregulated. FRE7 is expressed in cells limited in copper ion uptake by a Cu(I)-specific chelator or in cells lacking the high affinity Cu(I) permeases. The constitutive expression of FRE7 inMAC1 cells and the lack of expression in mac1–1 cells are consistent with Mac1 being the critical transcriptional activator of FRE7 expression. The 5′ promoter sequence of FRE7 contains three copper-responsive promoter elements. Two elements are critical for Mac1-dependent FRE7 expression. Combinations of either the distal and central elements or the central and proximal elements result in copper-regulated FRE7 expression. Spacing between Mac1-responsive sites is important as shown by the attenuated expression of FRE7 and CTR1 when two elements are separated by over 100 base pairs. From the three Mac1-responsive elements in FRE7, a new consensus sequence for Mac1 binding can be established as TTTGC(T/G)C(A/G).

1 June 2019 in Cell Host & Microbe
Verified
Journal Article
Closed access
DHDominik Hotter
Dominik Hotter
MBMatteo Bosso
Matteo Bosso
KJKasper L. Jønsson
Kasper L. Jønsson
CKChristian Krapp
Christian Krapp
CSChristina M. Stürzel
Christina M. Stürzel
FKFrank Kirchhoff
Frank Kirchhoff

1 September 2015 in Cell Host & Microbe
Verified
Journal Article
Closed access
LPLars Pache
Lars Pache
MDMiriam S. Dutra
Miriam S. Dutra
ASAdam M. Spivak
Adam M. Spivak
JMJohn M. Marlett
John M. Marlett
JMJeffrey Murry
Jeffrey Murry
SCSumit K. Chanda
Sumit K. Chanda

1 March 1990 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MCMark R. Colsman
Mark R. Colsman
TNTimothy D. Newbound
Timothy D. Newbound
Laura J MartinsLaura J Martins
Laura J Martins
MNMark D. Noirot
Mark D. Noirot
MMM. M. Miller
M. M. Miller
SSSteven H. Strauss
Steven H. Strauss

1 October 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ASAdam M. Spivak
Adam M. Spivak
ABAlberto Bosque
Alberto Bosque
ABAlfred Balch
Alfred Balch
DSDavid Smyth
David Smyth
Laura J MartinsLaura J Martins
Laura J Martins
VPVicente Planelles
Vicente Planelles
The human immunodeficiency virus type 1 (HIV-1) latent reservoir in resting CD4+T cells represents a major barrier to viral eradication. Small compounds capable of latency reversal have not demonstrated uniform responses acrossin vitroHIV-1 latency cell models. Characterizing compounds that demonstrate latency-reversing activity in resting CD4+T cells from aviremic patientsex vivowill help inform pilot clinical trials aimed at HIV-1 eradication. We have optimized a rapidex vivoassay using resting CD4+T cells from aviremic HIV-1+patients to evaluate both the bioactivity and latency-reversing potential of candidate latency-reversing agents (LRAs). Using this assay, we characterize the properties of two candidate compounds from promising LRA classes, ingenol 3,20-dibenzoate (a protein kinase C agonist) and panobinostat (a histone deacetylase inhibitor), in cells from HIV-1+antiretroviral therapy (ART)-treated aviremic participants, including the effects on cellular activation and cytotoxicity. Ingenol induced viral release at levels similar to those of the positive control (CD3/28 receptor stimulation) in cells from a majority of participants and represents an exciting LRA candidate, as it combines a robust viral reactivation potential with a low toxicity profile. At concentrations that blocked histone deacetylation, panobinostat displayed a wide range of potency among participant samples and consistently induced significant levels of apoptosis. The protein kinase C agonist ingenol 3,20-dibenzoate demonstrated significant promise in a rapidex vivoassay using resting CD4+T cells from treated HIV-1-positive patients to measure latent HIV-1 reactivation.